+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Diabetic Foot Ulcers - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762868
  • Report
  • April 2019
  • Region: Global
  • 145 pages
  • VPA Research


  • Anterogen Co Ltd
  • Cynata Therapeutics Ltd
  • Lakewood-Amedex Inc
  • NovaLead Pharma Pvt Ltd
  • Promore Pharma AB
  • Shionogi & Co Ltd

Diabetic Foot Ulcers pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Diabetic Foot Ulcers R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Diabetic Foot Ulcers report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Diabetic Foot Ulcers as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Diabetic Foot Ulcers with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Diabetic Foot Ulcers pipeline Profiled in detail

Key players actively participating in Diabetic Foot Ulcers pipeline are profiled along with their R&D progress in Diabetic Foot Ulcers treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Diabetic Foot Ulcers pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Diabetic Foot Ulcers treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Diabetic Foot Ulcers pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Diabetic Foot Ulcers pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Diabetic Foot Ulcers pipeline study
  • All recent news and developments related to Diabetic Foot Ulcers drugs are provided
Note: Product cover images may vary from those shown


  • Anterogen Co Ltd
  • Cynata Therapeutics Ltd
  • Lakewood-Amedex Inc
  • NovaLead Pharma Pvt Ltd
  • Promore Pharma AB
  • Shionogi & Co Ltd
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Diabetic Foot Ulcers Disease Overview

3. Diabetic Foot Ulcers R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Diabetic Foot Ulcers Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Diabetic Foot Ulcers Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Diabetic Foot Ulcers companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Diabetic Foot Ulcers Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • Anterogen Co Ltd
  • Aposcience AG
  • Aprogen Inc
  • Aurealis Pharma AG
  • CardioVascular BioTherapeutics Inc
  • Celularity Inc
  • Cynata Therapeutics Ltd
  • CytoTools AG
  • Energenesis Biomedical Co Ltd
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • Genentech Inc
  • Lakewood-Amedex Inc
  • MallInckrodt Plc
  • MangoGen Pharma Inc
  • MediWound Ltd
  • Mend Therapeutics
  • NovaLead Pharma Pvt Ltd
  • NuLife Sciences Inc
  • OliX Pharmaceuticals Inc
  • Oneness Biotech Co Ltd
  • Orbsen Therapeutics Ltd
  • ProMetic Life Sciences Inc
  • Promore Pharma AB
  • QBiotics Ltd
  • Remedor Biomed Ltd
  • Riptide Bioscience Inc
  • Shionogi & Co Ltd
  • Stempeutics Research Pvt Ltd
  • Suzhou Kintor Pharmaceutical Inc
  • SynDermix AG
  • TechnoPhage SA
  • TGV Laboratories Inc
  • Topadur Pharma AG
  • Transwell Biotech Co Ltd
  • USV Pvt Ltd
  • ViroMed Co Ltd
  • ZZ Biotech LLC
Note: Product cover images may vary from those shown